Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 3
2007 2
2008 1
2009 2
2010 1
2012 1
2013 2
2014 2
2015 3
2016 4
2017 2
2018 4
2019 5
2020 1
2021 6
2022 12
2023 7
2024 8
2025 8
2026 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

75 results

Results by year

Filters applied: . Clear all
Page 1
IRE1α silences dsRNA to prevent taxane-induced pyroptosis in triple-negative breast cancer.
Xu L, Peng F, Luo Q, Ding Y, Yuan F, Zheng L, He W, Zhang SS, Fu X, Liu J, Mutlu AS, Wang S, Nehring RB, Li X, Tang Q, Li C, Lv X, Dobrolecki LE, Zhang W, Han D, Zhao N, Jaehnig E, Wang J, Wu W, Graham DA, Li Y, Chen R, Peng W, Chen Y, Catic A, Zhang Z, Zhang B, Mustoe AM, Koong AC, Miles G, Lewis MT, Wang MC, Rosenberg SM, O'Malley BW, Westbrook TF, Xu H, Zhang XH, Osborne CK, Li JB, Ellis MJ, Rimawi MF, Rosen JM, Chen X. Xu L, et al. Among authors: dobrolecki le. Cell. 2024 Dec 12;187(25):7248-7266.e34. doi: 10.1016/j.cell.2024.09.032. Epub 2024 Oct 16. Cell. 2024. PMID: 39419025 Free PMC article.
A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology.
Guillen KP, Fujita M, Butterfield AJ, Scherer SD, Bailey MH, Chu Z, DeRose YS, Zhao L, Cortes-Sanchez E, Yang CH, Toner J, Wang G, Qiao Y, Huang X, Greenland JA, Vahrenkamp JM, Lum DH, Factor RE, Nelson EW, Matsen CB, Poretta JM, Rosenthal R, Beck AC, Buys SS, Vaklavas C, Ward JH, Jensen RL, Jones KB, Li Z, Oesterreich S, Dobrolecki LE, Pathi SS, Woo XY, Berrett KC, Wadsworth ME, Chuang JH, Lewis MT, Marth GT, Gertz J, Varley KE, Welm BE, Welm AL. Guillen KP, et al. Among authors: dobrolecki le. Nat Cancer. 2022 Feb;3(2):232-250. doi: 10.1038/s43018-022-00337-6. Epub 2022 Feb 24. Nat Cancer. 2022. PMID: 35221336 Free PMC article.
Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancer.
Bowling EA, Wang JH, Gong F, Wu W, Neill NJ, Kim IS, Tyagi S, Orellana M, Kurley SJ, Dominguez-Vidaña R, Chung HC, Hsu TY, Dubrulle J, Saltzman AB, Li H, Meena JK, Canlas GM, Chamakuri S, Singh S, Simon LM, Olson CM, Dobrolecki LE, Lewis MT, Zhang B, Golding I, Rosen JM, Young DW, Malovannaya A, Stossi F, Miles G, Ellis MJ, Yu L, Buonamici S, Lin CY, Karlin KL, Zhang XH, Westbrook TF. Bowling EA, et al. Among authors: dobrolecki le. Cell. 2021 Jan 21;184(2):384-403.e21. doi: 10.1016/j.cell.2020.12.031. Epub 2021 Jan 14. Cell. 2021. PMID: 33450205 Free PMC article.
PHGDH heterogeneity potentiates cancer cell dissemination and metastasis.
Rossi M, Altea-Manzano P, Demicco M, Doglioni G, Bornes L, Fukano M, Vandekeere A, Cuadros AM, Fernández-García J, Riera-Domingo C, Jauset C, Planque M, Alkan HF, Nittner D, Zuo D, Broadfield LA, Parik S, Pane AA, Rizzollo F, Rinaldi G, Zhang T, Teoh ST, Aurora AB, Karras P, Vermeire I, Broekaert D, Elsen JV, Knott MML, Orth MF, Demeyer S, Eelen G, Dobrolecki LE, Bassez A, Brussel TV, Sotlar K, Lewis MT, Bartsch H, Wuhrer M, Veelen PV, Carmeliet P, Cools J, Morrison SJ, Marine JC, Lambrechts D, Mazzone M, Hannon GJ, Lunt SY, Grünewald TGP, Park M, Rheenen JV, Fendt SM. Rossi M, et al. Among authors: dobrolecki le. Nature. 2022 May;605(7911):747-753. doi: 10.1038/s41586-022-04758-2. Epub 2022 May 18. Nature. 2022. PMID: 35585241 Free PMC article.
Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming.
Tian L, Goldstein A, Wang H, Ching Lo H, Sun Kim I, Welte T, Sheng K, Dobrolecki LE, Zhang X, Putluri N, Phung TL, Mani SA, Stossi F, Sreekumar A, Mancini MA, Decker WK, Zong C, Lewis MT, Zhang XH. Tian L, et al. Among authors: dobrolecki le. Nature. 2017 Apr 13;544(7649):250-254. doi: 10.1038/nature21724. Epub 2017 Apr 3. Nature. 2017. PMID: 28371798 Free PMC article.
Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer.
Anurag M, Jaehnig EJ, Krug K, Lei JT, Bergstrom EJ, Kim BJ, Vashist TD, Huynh AMT, Dou Y, Gou X, Huang C, Shi Z, Wen B, Korchina V, Gibbs RA, Muzny DM, Doddapaneni H, Dobrolecki LE, Rodriguez H, Robles AI, Hiltke T, Lewis MT, Nangia JR, Nemati Shafaee M, Li S, Hagemann IS, Hoog J, Lim B, Osborne CK, Mani DR, Gillette MA, Zhang B, Echeverria GV, Miles G, Rimawi MF, Carr SA, Ademuyiwa FO, Satpathy S, Ellis MJ. Anurag M, et al. Among authors: dobrolecki le. Cancer Discov. 2022 Nov 2;12(11):2586-2605. doi: 10.1158/2159-8290.CD-22-0200. Cancer Discov. 2022. PMID: 36001024 Free PMC article.
UBA1 inhibition sensitizes cancer cells to PARP inhibitors.
Awasthi S, Dobrolecki LE, Sallas C, Zhang X, Li Y, Khazaei S, Ghosh S, Jeter CR, Liu J, Mills GB, Westin SN, Lewis MT, Peng W, Sood AK, Yap TA, Yi SS, McGrail DJ, Sahni N. Awasthi S, et al. Among authors: dobrolecki le. Cell Rep Med. 2024 Dec 17;5(12):101834. doi: 10.1016/j.xcrm.2024.101834. Epub 2024 Dec 2. Cell Rep Med. 2024. PMID: 39626673 Free PMC article.
Proteogenomic characterization unveils biomarkers associated with chemoresistance in muscle-invasive bladder cancer.
Holt MV, Dou Y, Young MN, Saltzman AB, Anurag M, Lei JT, Jain A, Leng M, Kim BJ, Dobrolecki LE, Faucher SF, Savage S, Wang C, Shi Z, Villanueva H, Kremers K, Drinnon KD, Castro PD, Ittmann MM, Khatani MM, Kim SH, Ellis MJ, Zhang B, Malovannaya A, Lerner SP. Holt MV, et al. Among authors: dobrolecki le. Cell Rep Med. 2025 Aug 19;6(8):102255. doi: 10.1016/j.xcrm.2025.102255. Epub 2025 Jul 31. Cell Rep Med. 2025. PMID: 40749681 Free PMC article.
Integrative Proteogenomics and Forward Genetics Reveal a Novel Mitotic Vulnerability in Triple-Negative Breast Cancer.
Neill NJ, Satpathy S, Krug K, Meena JK, Ramesh Babu N, Calderon C, Reed D, Weber MJ, Dobrolecki LE, Lewis A, Sallas C, Anurag M, Holloway KR, Huang C, Vasaikar S, Cardenas MF, Kim BJ, Chan DW, Avanessian SC, Tyagi S, Orellana M, Mao S, Li H, Gong F, Kurley SJ, Meerbrey KL, Olson CM, Nair A, Sun T, Chung HC, Bowling EA, Wang JH, Zhang P, Xiao P, Yang D, Stossi F, Polley MC, Saltzman AB, Mundt F, Mani DR, Gillette MA, Hilsenbeck SG, Miles G, Gutierrez C, Osborne CK, Lin CY, Gray NS, Sun J, Wheeler DA, Perou CM, Malovannaya A, Lewis MT, Zhang B, Ellis MJ, Carr SA, Westbrook TF. Neill NJ, et al. Among authors: dobrolecki le. Cancer Discov. 2025 Nov 3;15(11):2326-2343. doi: 10.1158/2159-8290.CD-23-1173. Cancer Discov. 2025. PMID: 40778818 Free PMC article.
PRMT blockade induces defective DNA replication stress response and synergizes with PARP inhibition.
Li Y, Dobrolecki LE, Sallas C, Zhang X, Kerr TD, Bisht D, Wang Y, Awasthi S, Kaundal B, Wu S, Peng W, Mendillo ML, Lu Y, Jeter CR, Peng G, Liu J, Westin SN, Sood AK, Lewis MT, Das J, Yi SS, Bedford MT, McGrail DJ, Sahni N. Li Y, et al. Among authors: dobrolecki le. Cell Rep Med. 2023 Dec 19;4(12):101326. doi: 10.1016/j.xcrm.2023.101326. Cell Rep Med. 2023. PMID: 38118413 Free PMC article.
75 results